Patent office nixes MonoSol claim against BDSI over soluble film pain drug; Vascular Magnetics nails $7M series A for PAD drug delivery system;

> The U.S. Patent & Trademark Office has rejected all claims MonoSol filed against BioDelivery Sciences International regarding Onsolis, a soluble film cancer pain drug. Release

> Vascular Magnetics raised $7 million to fund development of its magnetically targeted drug delivery system to treat peripheral artery disease. System components include biodegradable, magnetic drug-loaded particles, a magnetic targeting catheter and an external device to create a uniform magnetic field. Release

> BioDelivery Sciences ($BDSI) earned a $15 million milestone payment from drug development partner Endo Pharmaceuticals, triggered because BioDelivery Sciences gained an extended exclusive patent for its BioErodible MucoAdhesive drug delivery technology. Release

> Medtronic ($MDT) gained FDA approval for its Resolute Integrity drug-eluting stent to treat coronary artery disease. Release

> U.K. biotech startup Critical Pharmaceuticals and The University of Nottingham will collaborate to develop a nano-enabled nasal spray version of teriparatide to treat osteoporosis. Release

> Drug developer Xenogenics in Rhode Island has obtained exclusive licensing rights to a patent granted to Rutgers University in Canada for polyanhydride drug delivery compounds. Release

> Niiki Pharma says its new gallium-based cancer treatment will be advancing to a Phase IIa clinical trial after showing that it could be more easily absorbed but maintain its composition until reaching its target. Release

Suggested Articles

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.

Swiss scientists are using ultrasound to trap and deliver drugs in the brain, a non-invasive delivery method that could help target tumors, too.